Development and validation of a screening assay for the evaluation of putative neuroprotective agents in the treatment of Parkinson's disease

Neurotoxicity Research

Volumn 19, Issue 4, 2011, Pages 519-526

  Yong Kee, C J ^a   Salomonczyk, D ^a   Nash, J E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cell death; Neuroprotection; Organelle dysfunction; Parkinson's disease; SH SY5Y

Indexed keywords

CAFFEINE; CREATINE; DOPAMINE; NAPHTHAZARIN; NEUROPROTECTIVE AGENT; NICOTINE; ROTENONE; SALICYLIC ACID; SELEGILINE; UBIDECARENONE;

ACCURACY; APOPTOSIS; ARTICLE; CELL ASSAY; CELL ORGANELLE; CELL PROTECTION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; MOLECULAR DYNAMICS; NEUROBLASTOMA CELL; NEUROPROTECTION; OXIDATIVE STRESS; PARKINSON DISEASE; PREDICTION; PRIORITY JOURNAL; RELIABILITY;

CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; CYTOTOXINS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; TREATMENT OUTCOME;

PARKINSONIA;

EID: 79958152676     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-010-9174-2     Document Type: Article

References (44)

1. Andres RH, Huber AW, Schlattner U, Perez-Bouza A, Krebs SH, Seiler RW, Wallimann T, Widmer HR (2005) Effects of creatine treatment on the survival of dopaminergic neurons in cultured fetal ventral mesencephalic tissue. Neuroscience 133:701-713 (Pubitemid 40798323)
2. Ardley HC, Scott GB, Rose SA, Tan NG, Robinson PA (2004) UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease. J Neurochem 90:379-391 (Pubitemid 38938224)
3. Bender A, Koch W, Elstner M, Schombacher Y, Bender J, Moeschl M, Gekeler F, Muller-Myhsok B, Gasser T, Tatsch K, Klopstock T (2006) Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology 67:1262-1264 (Pubitemid 44563840)
4. Betarbet R, Sherer TB, Greenamyre JT (2005) Ubiquitin-proteasome system and Parkinson's diseases. Exp Neurol 191(Suppl 1):S17-S27 (Pubitemid 40075408)
5. Canu N, Barbato C, Ciotti MT, Serafino A, Dus L, Calissano P (2000) Proteasome involvement and accumulation of ubiquitinated proteins in cerebellar granule neurons undergoing apoptosis. J Neurosci 20:589-599 (Pubitemid 30225561)
6. Ciechanover A (2005) Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 6:79-87
7. Cleren C, Yang L, Lorenzo B, Calingasan NY, Schomer A, Sireci A, Wille EJ, Beal MF (2008) Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. J Neurochem 104:1613-1621 (Pubitemid 351316765)
8. Dagda RK, Zhu J, Kulich SM, Chu CT (2008) Mitochondrially localized ERK2 regulates mitophagy and autophagic cell stress: implications for Parkinson's disease. Autophagy 4:770-782
9. Di Fonzo A et al (2007) ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology 68:1557-1562 (Pubitemid 46717978)
10. Ernster L, Dallner G (1995) Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1271:195-204
11. Ferger B, Teismann P, Earl CD, Kuschinsky K, Oertel WH (1999) Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice. Naunyn Schmiedebergs Arch Pharmacol 360:256-261 (Pubitemid 29480915)
12. Forsmark-Andree P, Lee CP, Dallner G, Ernster L (1997) Lipid peroxidation and changes in the ubiquinone content and the respiratory chain enzymes of submitochondrial particles. Free Radic Biol Med 22:391-400 (Pubitemid 27020112)
13. Hanrott K, Gudmunsen L, O'Neill MJ, Wonnacott S (2006) 6-Hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta. J Biol Chem 281:5373-5382 (Pubitemid 43847631)
14. Hara MR, Thomas B, Cascio MB, Bae BI, Hester LD, Dawson VL, Dawson TM, Sawa A, Snyder SH (2006) Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc Natl Acad Sci USA 103:3887-3889 (Pubitemid 43376650)
15. Heemskerk J, Tobin AJ, Ravina B (2002) From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials. Nat Neurosci 5 Suppl:1027-1029 (Pubitemid 35247190)
16. Hoglinger GU, Carrard G, Michel PP, Medja F, Lombes A, Ruberg M, Friguet B, Hirsch EC (2003) Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. J Neurochem 86:1297-1307 (Pubitemid 37022204)
17. Hornykiewicz O (1966) Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev 18:925-964
18. Jenner P (2003) Oxidative stress in Parkinson's disease. Ann Neurol 3:S26-S38
19. Kataoka M, Tonooka K, Ando T, Imai K, Aimoto T (1997) Hydroxyl radical scavenging activity of nonsteroidal anti-inflammatory drugs. Free Radic Res 27:419-427 (Pubitemid 28020047)
20. Kiffin R, Christian C, Knecht E, Cuervo AM (2004) Activation of chaperone-mediated autophagy during oxidative stress. Mol Biol Cell 15:4829-4840 (Pubitemid 39392200)
21. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N (1998) Mutations in the parkin gene cause autosomal recessive juvenile Parkinsonism. Nature 392:605-608 (Pubitemid 28207717)
22. Kragten E, Lalande I, Zimmermann K, Roggo S, Schindler P, Muller D, van Oostrum J, Waldmeier P, Furst P (1998) Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl. J Biol Chem 273:5821-5828 (Pubitemid 28124059)
23. Lai CT, Yu PH (1997) R(-)-deprenyl potentiates dopamine-induced cytotoxicity toward catecholaminergic neuroblastoma SH-SY5Y cells. Toxicol Appl Pharmacol 142:186-191
24. Matthews RT, Yang L, Browne S, Baik M, Beal M (1998) Coenzyme Q10 administration increases brain mitochondrial concentration and exerts neuroprotective effects. Proc Natl Acad Sci USA 95:8892-8897
25. Menke T, Gille G, Reber F, Janetzky B, Andler W, Funk RH, Reichmann H (2003) Coenzyme Q10 reduces the toxicity of rotenone in neuronal cultures by preserving the mitochondrial membrane potential. Biofactors 18:65-72 (Pubitemid 38030700)
26. Mohanakumar KP, Muralikrishnan D, Thomas B (2000) Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. Brain Res 864:281-290
27. Moon Y, Lee KH, Park JH, Geum D, Kim K (2005) Mitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone: protective effect of coenzyme Q10. J Neurochem 93:1199-1208 (Pubitemid 40776574)
28. Murray AM, Weihmueller FB, Marshall JF, Hurtig HI, Gottleib GL, Joyce JN (1995) Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with Parkinsonism. Ann Neurol 37:300-312
29. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, Lanciego JL, Artieda J, Gonzalo N, Olanow CW (2000) Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 23:S8-19
30. Olanow CW (2008) Levodopa/dopamine replacement strategies in Parkinson's disease-future directions. Mov Disord 23(Suppl): S613-S622
31. Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, Schwartz SL, DiProspero NA, Knight MA, Schuldiner O, Padmanabhan R, Hild M, Berry DL, Garza D, Hubbert CC, Yao TP, Baehrecke EH, Taylor JP (2007) HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 447:859-863 (Pubitemid 46920134)
32. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT (2002) Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 5:731-736 (Pubitemid 34827590)
33. Paterson IA, Zhang D, Warrington RC, Boulton AA (1998) R-deprenyl and R-2-heptyl-N-methylpropargylamine prevent apoptosis in cerebellar granule neurons induced by cytosine arabinoside but not low extracellular potassium. J Neurochem 70:515-523 (Pubitemid 28079340)
34. Ramirez A, Heimbach A, Grundemann J, Stiller B, Hampshire D, Cid LP, Goebel I, Mubaidin AF, Wriekat AL, Roeper J, Al-Din A, Hillmer AM, Karsak M, Liss B, Woods CG, Behrens MI, Kubisch C (2006) Hereditary Parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 38:1184-1191 (Pubitemid 44470365)
35. Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, Marler JR (2003) Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 60:1234-1240 (Pubitemid 36460976)
36. Schapira AH (2006) Mitochondrial disease. Lancet 368:70-82
37. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M (2002) Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59:1541-1550
38. Simon DK, Swearingen CJ, Hauser RA, Trugman JM, Aminoff MJ, Singer C, Truong D, Tilley BC (2008) Caffeine and progression of Parkinson disease. Clin Neuropharmacol 31:189-196
39. Somayajulu-Nitu M, Sandhu JK, Cohen J, Sikorska M, Sridhar TS, Matei A, Borowy-Borowski H, Pandey S (2009) Paraquat induces oxidative stress, neuronal loss in substantia nigra region and Parkinsonism in adult rats: neuroprotection and amelioration of symptoms by water-soluble formulation of coenzyme Q10. BMC Neurosci 10:88
40. Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner WJ (2006) Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66:976-982 (Pubitemid 44044779)
41. Testa CM, Sherer TB, Greenamyre JT (2005) Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res Mol Brain Res 134:109-118 (Pubitemid 40403643)
42. Tuite P, Riss J (2003) Recent developments in the pharmacological treatment of Parkinson's disease. Expert Opin Investig Drugs 12:1335-1352 (Pubitemid 36949693)
43. Xie YX, Bezard E, Zhao BL (2005) Investigating the receptor-independent neuroprotective mechanisms of nicotine in mitochondria. J Biol Chem 280:32405-32412 (Pubitemid 41361851)
44. Yang L, Calingasan NY, Wille EJ, Cormier K, Smith K, Ferrante RJ, Beal MF (2009) Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J Neurochem 109:1427-1439